Efficacy Evaluation of 5-Fluorouracil as an Adjuvant to Endoscopic Dacryocystorhinostomy in Managing Primary Acquired Nasolacrimal Duct Obstruction With Small Lacrimal Sac: A Randomized Controlled Study

NCT07154121 | Recruiting

• 1 other identifier: 2025KYPJ065
• Study Type: interventional
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

Primary acquired nasolacrimal duct obstruction (PANDO) is a lacrimal duct obstruction disease characterized by inflammatory fibrosis of the nasolacrimal duct, with primary symptoms including epiphora and increased secretions, commonly seen in middle-aged and elderly women over 40 years of age . The pathogenesis of PANDO remains unclear, and there are no effective pharmacological treatments. Dacryocystorhinostomy (DCR) is currently considered the primary treatment for PANDO, as it restores tear drainage by creating an alternative drainage pathway between the lacrimal sac and the nasal cavity. The surgical techniques for DCR primarily include external DCR (Ex-DCR) and endoscopic DCR (En-DCR), with En-DCR first proposed by McDonogh and Meiring in 1989. In recent years, with the advancement of endoscopic sinus surgery techniques, En-DCR has gained widespread recognition in the treatment of PANDO, as it not only minimizes surgical trauma and accelerates postoperative recovery but also leaves no external scars. In recent years, with the advancement of endoscopic surgical techniques, En-DCR has gained widespread recognition in the treatment of PANDO, as it not only causes minimal surgical trauma and facilitates rapid postoperative recovery; but also leaves no external scars, making it more aesthetically pleasing; and can simultaneously correct nasal cavity abnormalities such as deviated nasal septum and sinusitis. Recent studies indicate that the surgical success rate of En-DCR can reach 84%-94%, comparable to traditional external surgery Recent studies have shown that the surgical success rate of En-DCR can reach 84%-94%, comparable to traditional external approaches. Although the prognostic factors associated with En-DCR outcomes have not yet been fully elucidated, it has been demonstrated that lacrimal sac size is one of the key indicators for predicting the efficacy of En-DCR surgery, and a small lacrimal sac is a major risk factor for En-DCR surgical failure. In patients with normal-sized lacrimal sacs, creating a larger bone window can better expose the lacrimal sac, thereby forming a larger lacrimal sac flap, making the lacrimal sac opening wider, and reducing the risk of postoperative obstruction. However, in patients with small lacrimal sacs, even if the bone window is intentionally enlarged during surgery, the resulting lacrimal sac flap remains small due to the inherent small size of the lacrimal sac, making it difficult to achieve proper alignment with the nasal mucosal flap at the anterior margin of the hook process, resulting in poor anastomotic outcomes. In PANDO cases, the primary cause of surgical failure is often related to abnormal healing of the anastomotic site postoperatively, particularly scar formation at the surgical site and scar-induced closure of the bone window. Compared to patients with normal-sized lacrimal sacs, patients with small lacrimal sacs are more prone to osteotomy site closure due to granulation tissue proliferation postoperatively, thereby reducing surgical successrates. Therefore, preventing fibrous proliferation at the osteotomy site may be key to improving the success rate of En-DCR treatment for small lacrimal sac-type PANDO. Antimetabolite drugs are frequently used to treat various ocular lesions characterized by non-tumor cell proliferation. 5-Fluorouracil (5-FU) is one such drug, which inhibits DNA synthesis by blocking thymidine kinase, an enzyme involved in collagen gene expression. In vitro studies have shown that 5-FU interferes with the biosynthesis of F-actin and prevents fibroblast migration; 5-FU can inhibit scar formation by suppressing fibroblast proliferation; and 5-FU can prolong wound healing time. 5-FU is now widely used to inhibit fibroblast proliferation and scar formation within the filter after glaucoma filtration surgery, demonstrating good safety and efficacy. This study is the first to explore the efficacy of 5-fluorouracil as an adjunct to En-DCR therapy for small lacrimal sac PANDO, aiming to provide a new adjunctive treatment strategy for patients with small lacrimal sac PANDO.

Conditions

Primary Acquired Nasolacrimal Duct Obstruction

Outcome Measures

Primary Outcomes (1)

• Surgical success rate in patients with small lacrimal sac type PANDO at six months post-En-DCR surgery

  Surgical success is defined as: the patient is asymptomatic/has improved symptoms and has a FICI score of ≥3 on endoscopic examination.

  Six months after surgery

Secondary Outcomes (3)

• Surgical success rates for small lacrimal sac type PANDO patients at three weeks and three months post-En-DCR surgery

  three weeks and three months after surgery

• Changes in stoma size three months after surgery

  three months after surgery

• Incidence of complications during treatment

  Six months after surgery

Study Arms (2)

experimental group

EXPERIMENTAL

Drug: 5-fluorouracil group

control group

ACTIVE COMPARATOR

Other: saline group

Interventions

5-fluorouracil group DRUG

Patients in the intervention group underwent standard En-DCR surgery, with all procedures performed by the same senior oculoplastic surgeon; After suturing to create a new nasolacrimal duct during surgery, Schirmer strips were placed at the ostium to measure its size and photographed for record-keeping. The ostium was then covered with a gelatin sponge soaked in 12.5 mg/mL 5-fluorouracil for 3 minutes, after which the gelatin sponge was removed and the area thoroughly rinsed with saline.

experimental group

saline group OTHER

Patients in the intervention group underwent standard En-DCR surgery, with all procedures performed by the same senior oculoplastic surgeon; Similarly, after suturing to create a new nasolacrimal duct during surgery, Schirmer strips were placed at the ostium to measure its size and photographed for record-keeping. The ostium was then covered with a gelatin sponge soaked in saline solution for 3 minutes, after which the gelatin sponge was removed and the ostium was thoroughly rinsed with saline solution.

control group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients diagnosed with small lacrimal sac-type PANDO based on clinical symptoms, lacrimal duct irrigation, and CT lacrimal duct angiography (minimum diameter on lacrimal sac angiography ≤3 mm);
• Patients aged 18 years or older;
• Patients with no history of drug allergies (including 5-FU, contrast agents, or other substances that may affect participation in this study);
• Patients who have provided informed consent and signed the informed consent form.

You may not qualify if:

• Previously underwent nasolacrimal duct surgery;
• Nasolacrimal duct obstruction secondary to facial surgery, sinus disease, tumors, trauma, or revision DCR;
• Severe sinusitis or deviated nasal septum;
• Acute dacryocystitis;
• Patients with chronic debilitating conditions such as diabetes, malignant tumors, or malnutrition;
• Patients with systemic diseases such as sarcoidosis or Wegener's granulomatosis that may promote scar formation.

Sponsors & Collaborators

• Zhongshan Ophthalmic Center, Sun Yat-sen University: lead

Study Sites (1)

Zhongshan Ophthalmic Center

Guangzhou, Guangdong, 510060, China

RECRUITING

Central Study Contacts

Xuanwei Liang

CONTACT

+8613694220662; liangxuanwei@163.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 27, 2025
• First Posted: September 4, 2025
• Study Start: September 8, 2025
• Primary Completion (Estimated): July 1, 2026
• Study Completion (Estimated): July 1, 2026
• Last Updated: September 9, 2025

Record last verified: 2025-07

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)